Document is current
Any future updates will be listed below
-
Authors
Bonavia, Anthony S. http://orcid.org/0000-0001-9596-001X
Samuelsen, Abigail
Liang, Menglu
Hanson, Jodi
McKeone, Daniel
Chroneos, Zissis C.
Halstead, E. Scott
-
Funding
Funding for this research was provided by:
National Institute of General Medical Sciences (K08GM138825)
- License Information
-
More Information
Article History
Received: 5 May 2023
Accepted: 4 October 2023
First Online: 13 October 2023
Declarations
:
: All participants were enrolled at the Penn State Milton S Hershey Medical Center (Hershey, PA), following ethical approval by the Human Studies Protection Office of the Penn State College of Medicine (Approval #15328 (7/30/2020) and #10357 (11/8/2018). Human research was performed in accordance with standards established based on the Helsinki Declaration of 1975. Informed consent was obtained from patients having decision-making capacity, or from the legally authorized healthcare representatives of patients lacking decision-making capacity. This observational study was registered on Clinicaltrials.gov with ID# NCT03146546.
: Not applicable.
: JH is an employee of CTL Immunospot and has performed blinded quantification of ELISpot data. She did not participate in funding, data acquisition or data analysis. ESH is a speaker for Swedish Orphan Biovitrum (SOBI) pharmaceuticals and lectures specifically about the disease process and therapeutic strategies for Hemophagocytic lymphohistiocytosis. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
